Gut Microbiome Therapies in MS, Alzheimer’s, and ALS: The Evidence

The gut-brain story extends far beyond Parkinson's—but clinical proof has not caught up

Gut dysbiosis appears across Parkinson's disease, Alzheimer's disease, multiple sclerosis, and ALS. Researchers have plausible routes by which gut microbes could affect the brain: short-chain fatty acids (SCFAs), gut-barrier function, immune signaling, and inflammation. But a plausible route is not a treatment result. Outside Parkinson's disease, probiotic and microbiome-targeted therapies have not shown that they slow neurological disease.

Parkinson's has the most developed randomized-trial evidence. A 2025 meta-analysis of randomized controlled trials found that gut microbiota-targeted therapies used as adjunct treatments improved several Parkinson's outcomes, including motor scores on MDS-UPDRS III (standardized mean difference [SMD] −0.34; 95% confidence interval [CI], −0.57 to −0.11; P = 0.004). The authors described the interventions as promising, not established care. That is the current high-water mark for this field. Gu et al.'s 2025 review gives the most encouraging randomized evidence, but it does not validate microbiome treatment for every neurological condition.

For MS, Alzheimer's, and ALS, the biology merits research. The clinical evidence calls for restraint.

Why SCFAs and Lactiplantibacillus plantarum attract attention

SCFAs are compounds made when gut microbes ferment dietary material. Butyrate, one of the best known, has drawn particular interest because reduced butyrate-producing bacteria have been reported in ALS and other neurological conditions. The proposed chain runs from altered gut ecology to lower SCFA production, impaired intestinal-barrier function, immune activation, neuroinflammation, and neuronal injury.

Each link is biologically plausible, but human probiotic trials in diagnosed MS, Alzheimer's, and ALS have not confirmed the whole chain with coordinated measures of SCFAs, gut permeability, and downstream neuroinflammation. A microbiome shift is a biomarker result; it does not prove that the shift changes a person's disease course.

Lactiplantibacillus plantarum, also called Lactobacillus plantarum in older naming systems, is a useful case study. A 2024 systematic review covering 20 studies identified it as the most studied individual strain across neurological conditions. The review catalogued preclinical mechanisms that include SCFA production, tighter intestinal junctions, lower TNF-α and IL-6 signaling, and higher BDNF. Its stronger human data came from Parkinson's disease and mild cognitive impairment, however—not diagnosed Alzheimer's disease, MS, or ALS. Beltrán-Velasco et al. found far more animal-model evidence than useful human trial evidence outside Parkinson's.

Multiple sclerosis: three trials, 173 participants, and a pooling problem

MS has the fullest randomized probiotic dataset among the non-Parkinson's conditions, but it remains small and difficult to interpret. A 2021 meta-analysis by Jiang et al. pooled three eligible randomized controlled trials involving 173 people with MS. The trials varied in probiotic formulation, dose, treatment duration, MS subtype, disease duration, and use of immunomodulatory treatment. They were not necessarily estimating the same intervention effect.

The headline pooled results look favorable at first glance. For disability, measured by the Expanded Disability Status Scale (EDSS), the pooled SMD was −1.22 (95% CI, −2.40 to −0.03; P = 0.04). For depression on the Beck Depression Inventory, the SMD was −1.58 (95% CI, −3.03 to −0.12; P = 0.03). Both estimates reached conventional statistical significance. Yet heterogeneity was extreme: I² was 92% for EDSS and 94% for depression. Those values mean the trial results differed sharply, so the pooled estimates do not provide a dependable common effect size.

The more consistent findings involved psychological secondary outcomes: General Health Questionnaire scores improved with an SMD of −0.71 and DASS scores with an SMD of −0.72, both with I² = 0%. These results are more interpretable statistically, but they are not evidence that probiotics alter MS disability or progression. Jiang et al. rated the overall certainty of evidence as very low. The 2021 MS meta-analysis therefore supports a research signal for mood and wellbeing, not a disease-modifying recommendation.

A broader 2025 review of probiotics and depression offers a plausible context for those mood findings: across 12 randomized trials, its meta-analysis reported lower depressive symptoms versus placebo, with a mean difference of −1.94 (95% CI, −3.56 to −0.32). That literature does not establish efficacy in MS, but it makes a psychological effect more believable than a conclusion about neurological disability. Sulaiman et al. also describes gut-brain signaling and inflammatory changes as candidate mechanisms, not proof of a mechanism in people with MS.

Alzheimer's disease: encouraging cognitive signals, short of a clinical answer

Alzheimer's probiotic studies have generally reported favorable cognitive directions. A 2025 systematic review and meta-analysis focused specifically on probiotic supplementation and cognitive outcomes in Alzheimer's disease found positive signals, but it drew on a small, short-duration evidence base. Liu et al.'s review does not provide the kind of large, long-term controlled evidence needed to judge whether an intervention changes a progressive neurological disease.

Microbiome-focused findings are similarly preliminary. A 2025 systematic review of Lactobacillus strains in Alzheimer's disease reported favorable changes in gut microbiome parameters, including studies involving L. plantarum. Those changes matter as evidence that supplementation can affect gut ecology. They do not show that a particular strain preserves cognition, slows decline, or changes brain pathology. Quansah et al. examined microbiome-related outcomes, not definitive disease-modification endpoints.

A 2024 cross-disease systematic review reached the appropriately cautious conclusion: human Alzheimer's findings are preliminary and need larger cohorts, longer follow-up, comprehensive neuropsychiatric and metabolic testing, biochemical measures, and neuroimaging. Mincic et al. also notes that disease stage and existing medications can affect responses, variables that small trials often cannot properly handle.

ALS: a mechanistic hypothesis without controlled efficacy data

ALS presents the widest gap between a persuasive biological rationale and clinical evidence. Reviews report dysbiosis patterns that include fewer butyrate-producing bacteria and more pathobionts. That supports studying diet, prebiotics, probiotics, synbiotics, and fecal microbiota transplantation. It does not establish that any of them improve motor function or survival.

The available cross-disease reviews have not identified completed controlled human trials of these interventions with ALS progression or survival endpoints. Mincic et al. found that human research remains sparse relative to animal research. Results in cell culture and animal models can help select what to test next; they cannot tell a person with ALS that a probiotic will change the disease.

What the evidence supports today

The gut-brain axis is legitimate biology. Dysbiosis and microbial metabolites deserve serious study in neuroinflammation and neurodegeneration. The main obstacle is translational: small trials use different formulations, different treatment durations—often 8 to 16 weeks—and different patient populations. Publication bias adds another concern, since small supplement studies with positive trends are more likely to appear in print than null results.

For diagnosed MS, Alzheimer's disease, or ALS, no probiotic—including L. plantarum—has controlled evidence showing that it modifies disease progression.

Someone choosing a probiotic for general gut health may reasonably view L. plantarum as a strain with more neurological mechanistic review support than many alternatives. That is an inference from preclinical work and limited human research, not a neurological treatment recommendation. Parkinson's trials provide a reason to keep watching this area. MS requires better, stage-stratified trials; Alzheimer's needs larger and longer cognitive trials; and ALS needs controlled human intervention studies before efficacy claims can begin.